Oral vs Injectable GLP-1
Published Jul 3, 2026 · Updated Nov 9, 2026 · 5 minute read
For years, GLP-1 meant an injection. Now there are pills too, and not all pills work the same way. The route you take a GLP-1 changes the daily routine, the dosing rules, and the convenience, even when the receptor it targets is identical.
Key Takeaways
- GLP-1 medicines now come in two routes: injections and oral tablets.
- Most injectables are once-weekly peptides given under the skin (Ozempic, Wegovy, Mounjaro, Zepbound).
- Oral peptide GLP-1s (Rybelsus, Ozempic tablets, the Wegovy pill) need strict empty-stomach dosing because peptides absorb poorly by mouth.
- Rybelsus is being discontinued and replaced by Ozempic tablets, whose milligram strengths are different and not interchangeable with it number for number.
- Orforglipron (Foundayo) is a non-peptide oral GLP-1 without the same food and water restrictions.
- Route changes convenience and dosing rules, not which receptor the drug targets.
- This page is educational and is not medical advice.
1. The Two Routes
A GLP-1 receptor agonist can be delivered as an injection or as an oral tablet. The receptor target is the same; what changes is how the drug gets into the body.
| Injectable GLP-1 | Oral GLP-1 | |
|---|---|---|
| Form | Subcutaneous injection | Tablet |
| Typical schedule | Once weekly | Once daily |
| Examples | Ozempic, Wegovy, Mounjaro, Zepbound | Ozempic tablets, Wegovy tablets, Foundayo, Rybelsus (being discontinued) |
| Dosing rules | Inject and go | Varies by product (see below) |
2. Why Oral Peptides Are Tricky
Most GLP-1 drugs are peptides, and peptides are fragile in the digestive tract. The gut breaks them down, and very little crosses into the bloodstream, which is the problem of low oral bioavailability. That is why GLP-1s started as injections: an injection bypasses the gut entirely.
To make an oral peptide work, manufacturers add an absorption enhancer and require strict timing. Rybelsus, Ozempic tablets, and the oral Wegovy pill (all oral semaglutide) must be taken on an empty stomach with only a small sip of water, followed by a waiting period before eating or drinking anything else.
3. The Non-Peptide Exception
Not every oral GLP-1 is a peptide. Orforglipron, sold as Foundayo, is a non-peptide, small-molecule GLP-1. Because it is not a peptide, it survives digestion better and is designed to be taken without the strict food and water timing that oral semaglutide requires.
| Oral product | Type | Food/water rules |
|---|---|---|
| Rybelsus (being discontinued) | Oral peptide (semaglutide), 3 to 14 mg daily | On waking, empty stomach, up to 4 oz of water, wait 30 minutes |
| Ozempic tablets | Oral peptide (semaglutide), 1.5 to 9 mg daily, on the Rybelsus label and replacing Rybelsus | Same rule as Rybelsus |
| Wegovy tablets | Oral peptide (semaglutide), 1.5 to 25 mg daily | Same rule as Rybelsus |
| Foundayo | Non-peptide small molecule (orforglipron), 0.8 to 17.2 mg daily | With or without food; no water limit |
FDA’s drug shortage data list Rybelsus as To Be Discontinued, to be replaced by Ozempic tablets, though it is still listed on Drugs@FDA and DailyMed. The strengths do not match by number. The shared label pairs Rybelsus 7 mg with Ozempic tablets 4 mg and 14 mg with 9 mg, and says the two are not substitutable milligram for milligram, so any switch belongs with a prescriber.
4. Trade-Offs of Each Route
Neither route is universally better; they trade different things.
- Injectables: once weekly, no daily food-timing rules, but require an injection and cold-chain or storage considerations.
- Oral peptides: no needles, but daily dosing with strict empty-stomach timing.
- Non-peptide orals: daily, needle-free, and more flexible timing.
5. The Same Receptor, Different Delivery
It is worth repeating the core point: changing the route does not change which receptor the drug activates. Oral and injectable semaglutide are both GLP-1 agonists. The difference is logistics, absorption, and routine, not mechanism. For the molecule itself, see What Is Semaglutide?.
6. Tracking Across Routes
Whether you take a shot or a pill, consistent records help: log the product, dose, and timing, and for injectables also the injection site. Oral logs benefit from noting the empty-stomach timing. See how GLP-1 tracking works.
7. Oral vs Injectable GLP-1 FAQ
What is the difference between oral and injectable GLP-1?
The route. Injectable GLP-1s are usually once-weekly shots given under the skin, while oral GLP-1s are daily tablets. The route changes convenience and dosing rules, but both activate the same GLP-1 receptor.
Why do oral GLP-1 peptides have strict dosing rules?
Peptides are broken down in the gut and absorb poorly by mouth, which is low oral bioavailability. Oral semaglutide products (Rybelsus, Ozempic tablets, and the Wegovy pill) use an absorption enhancer and must be taken on an empty stomach with a small sip of water, then wait before eating, to absorb reliably.
Is there an oral GLP-1 without food restrictions?
Orforglipron (sold as Foundayo) is a non-peptide, small-molecule oral GLP-1. Because it is not a peptide, it is designed to be taken without the strict food and water timing that oral semaglutide requires.
Are pills as effective as injections?
Effectiveness depends on the specific drug and dose, not the route alone. This page explains how the routes differ; it does not rank products or give medical advice. Which option fits a person is a clinical decision for a prescriber.
Which GLP-1s are injectable and which are oral?
Injectable: Ozempic, Wegovy, Mounjaro, and Zepbound. Oral: Rybelsus (being discontinued), Ozempic tablets, and the Wegovy pill (all oral semaglutide), and Foundayo (orforglipron, a non-peptide tablet).
8. Sources
References used for this article
- NCBI Bookshelf: Physiology, Incretin (GLP-1)
- MedlinePlus: Semaglutide (oral)
- FDA: Drugs@FDA database (GLP-1 approvals)
- Eli Lilly: Foundayo (orforglipron) approval announcement
- DailyMed: Rybelsus and Ozempic tablets (oral semaglutide) prescribing information
- DailyMed: Foundayo (orforglipron) tablets prescribing information
- DailyMed: Wegovy (semaglutide) injection and tablets prescribing information
- FDA drug shortage data (openFDA): Rybelsus 3, 7, and 14 mg listed as To Be Discontinued, to be replaced by Ozempic tablets (June 4, 2026)